Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa

Harry O. Orlans, Michelle E. McClements, Alun R. Barnard, Cristina Martinez-Fernandez de la Camara & Robert E. MacLaren

Rhodopsin (RHO) gene mutations are a common cause of autosomal dominant retinitis pigmentosa (ADRP). The need to suppress toxic protein expression together with mutational heterogeneity pose challenges for treatment development. Mirtrons are atypical RNA interference effectors that are spliced from transcripts as short introns. Here, we develop a novel mirtron-based knockdown/replacement gene therapy for the mutation-independent treatment of RHO-related ADRP, and demonstrate efficacy in a relevant mammalian model. Splicing and potency of rhodopsin-targeting candidate mirtrons are initially determined, and a mirtron-resistant codon-modified version of the rhodopsin coding sequence is validated in vitro. These elements are then combined within a single adeno-associated virus (AAV) and delivered subretinally in a RhoP23H knock-in mouse model of ADRP. This results in significant mouse-to-human rhodopsin RNA replacement and is associated with a slowing of retinal degeneration. This provides proof of principle that synthetic mirtrons delivered by AAV are capable of reducing disease severity in vivo.
Inherited retinal diseases (IRDs) such as retinitis pigmentosa (RP) are the most common cause of irreversible sight loss in the young. The development of gene replacement therapy using adeno-associated viral (AAV) vectors has led to the market approval of Luxturna for the treatment of Leber congenital amaurosis type 2 (LCA2) and AAV-based therapeutics for other IRDs are showing promise in early-phase clinical trials. Mutations in the rhodopsin gene (RHO) are frequently responsible for autosomal dominant (AD) RP. This gene encodes a seven-transmembrane protein that is responsible for initiating the rod phototransduction cascade. In rhodopsin-related RP, rods degenerate after which cone cells are lost by secondary mechanisms. The mechanisms through which mutant rhodopsin proteins cause rod cell dysfunction and death vary by mutation, but may be broadly categorised into those that have dominant negative effects and those that induce direct cellular toxicity. In contrast to gene therapy for recessive diseases such as LCA2, where simple gene augmentation may be sufficient, treatment of dominant diseases may require suppression of a toxic mutant protein.

RNA interference (RNAi) is an important naturally-occurring mode of eukaryotic gene regulation whereby short single-stranded RNAs target specific transcripts for degradation through base pair complementarity. Canonical effectors of RNAi known as micro (mi)RNAs originate from hairpin-like structures often found within introns. These are cleaved from genomically-derived mRNAs at their 5' end by a microprocessing complex consisting of the enzyme Drosha and its cofactor DGCRR8. RNAi has been applied to therapy as a method of gene silencing, in particular for the treatment of dominantly-inherited diseases. Artificial miRNAs, driven by RNA polymerase II (Pol-II) promoters as well as short hairpin (sh) RNAs driven by RNA polymerase III (Pol-III) promoters have been developed for this purpose. Mutational heterogeneity represents a significant challenge for application of RNAi for dominant diseases such as rhodopsin-related ADRP, suggesting the requirement for sequence-specific effectors for each point mutation within a gene. An innovative solution is the so-called knockdown/replacement paradigm. Here both wild-type and mutant alleles are indiscriminately targeted for suppression by a single effector. At the same time, a version of the wild-type gene modified to render it resistant to this effector, most commonly through use of synonymous codons at the target site, is co-delivered. For the case of RNAi, this mutation-independent approach constitutes RNA replacement and has been successfully applied to animal models of dominant disease.

Several key barriers however exist for the translation of RNAi-based knockdown/replacement gene therapies to clinical trial. Firstly, the expression of the two arms of the therapy within target cells must be carefully balanced. Indeed, Pol-III-driven shRNA may cause cellular toxicity through saturation of endogenous processing systems, whilst transgene overexpression, particularly in the case of rhodopsin, may be similarly toxic. Secondly, off-target effects must be minimised. The 5' cleavage site within RNAi hairpins by Drosha/DGCR8 is notoriously variable. The result is a mixed population of mature miRNAs with variations present at the critical 5' end region, which risks unanticipated suppression of unintended transcripts. Thirdly, the possibility of off-target effects in bystander cell populations such as cones and the retinal pigment epithelium (RPE) for IRD treatment must be considered. Delivery of shRNAs under control of Pol-III promoters such as H1 and U6 has been commonly used for knockdown/replacement therapy, but as these promoters lack cellular specificity, significant expression in non-targeted cells would be expected.

One novel approach that addresses these concerns uses artificial mirtrons as effectors of RNAi. Mirtrons form an atypical sub-class of naturally-occurring pre-miRNA. These hairpin-like structures are spliced from pre-miRNAs as short introns. Unlike canonical miRNAs, their often critical 5' end is precisely defined by the splicing machinery. Mirtron-RNAi guide strand generation is thus Drosha/DGCR8-independent, resulting in greater accuracy and avoiding a potential molecular bottleneck. Since mirtrons may be expressed by cell-specific Pol-II promoters, overexpression-related toxicity is unlikely, and off-target effects in unintended cell populations are minimised. Further, as mirtrons may be expressed bicistronically with a transgene by a common promoter, very precise spatiotemporal matching of the two arms of a knockdown/replacement gene therapy may be achieved.

Gene silencing using artificial mirtrons has been shown in cell culture systems and mirtron-mediated knockdown/replacement of the ataxin-7 gene has been demonstrated in vitro. Achieving a construct capable of efficient knockdown together with adequate gene supplementation, an essential requirement for the treatment of dominant disease, has been a significant challenge. Furthermore, efficacy of artificial mirtrons in vivo has not been previously demonstrated.

In this study we have designed and validated artificial mirtrons directed against rhodopsin, and developed a cell-specific expression system for knockdown/replacement gene therapy application that provides significant target gene knockdown without compromise of transgene expression. We show that this expression cassette can drive RNA-replacement when delivered to the mammalian retina by AAV in vivo, and demonstrate an associated rescue effect in a relevant mouse model of rhodopsin-related ADRP.

Results
Splicing efficiency and potency of artificial mirtrons in vitro. Seven candidate mirtrons (M1–M7) were designed to target both mouse and human rhodopsin transcripts so a vector validated in the former species may be suitable for clinical trial. Two versions of M5 differing by two nucleotides were established to account for differences in the human/mouse target sequence (designated M5H and M5M respectively). Design methodology and in silico analysis are described within the methods. To determine splicing efficiency, each mirtron was individually cloned into the coding sequence of enhanced green fluorescent protein (eGFP) as an artificial intron (M1-GFP to M7-GFP plasmids; Fig. 1a). Failure to accurately splice should abolish eGFP expression so that eGFP-derived fluorescence reflects splicing efficiency of nested mirtrons. Following transfection of HEK293 cells, fluorescent signal was detected in all cases but strength varied significantly for the seven mirtron designs (Fig. 1b, c).

To investigate splice variants, cDNA was derived from transfected cells and a set of mirtron-spanning primers directed against the flanking eGFP sequence was used to amplify the spliced region. Resulting amplicons corresponded to various splice products: a 225 bp band represented accurate splicing, a 301 bp band represented unspliced mRNA, whilst intermediate bands indicated mis-spliced transcripts resulting from cryptic splice donor/acceptor sites within mirtrons (Fig. 1d, e). These data confirm that rhodopsin-targeting synthetic mirtrons may be spliced as artificial introns in vitro, although efficiency and accuracy of this process is sequence-dependent.

Potency of candidate mirtrons directed against human/mouse rhodopsin was determined in vitro using a dual luciferase assay (Dual Glo®, Promega, UK). Significant knockdown was observed for M2 and M3, and for each version of M5 against its
corresponding rhodopsin species. No knockdown was apparent for M5 against mouse rhodopsin, or for M5 against human rhodopsin, suggesting intolerance of guide strand-target mismatches (Fig. 1f). The effect of the most potent mirtron (M3) against selected putative off-targets was explored with no activity detected (Supplementary note 1).

**Delivery of artificial mirtrons within the 5′-UTR of a transgene.** Placement of mirtrons within the CDS for knockdown/replacement gene therapy may adversely affect transgene expression, whilst placement within the 3′-UTR might similarly result in nonsense-mediated decay (NMD). The mechanism of NMD is suggested to rely upon detection of exon-exon junctional complexes (EJCs). These protein complexes are deposited 20–24 nucleotides upstream of 5′ splice sites after splicing, and are usually removed by ribosomes during translation. Introns downstream of a stop codon will not have their EJCs removed in this way as the ribosome has already separated from the transcript. The presence of retained EJCs on mRNA is thought to be the trigger for NMD. Indeed, a premature stop codon induces NMD of the transcript in this manner. On this basis, we reasoned that placing mirtrons downstream of the stop codon of our transgene (i.e. in the 3′-UTR) might trigger degradation of the whole transcript. We therefore explored placing the most effective mirtrons within the 5′-UTR of a transgene (eGFP) in vitro (Fig. 2a). All were more potent in this configuration than when nested within the CDS for both human and mouse rhodopsin targets (Fig. 2b) PCR splice analysis indicated a significantly greater proportion of correctly spliced transcripts for 5′-UTR than for nested mirtrons. Sanger sequencing of the smallest band confirmed that this corresponded to correctly-spliced mRNA (Fig. 2c). When multiple mirtrons were included in tandem within the 5′-UTR of eGFP (either two copies of M3 or one copy each of M3 and M5), both appeared to splice independently (Fig. 2f, g), and their rhodopsin-suppressing effects were additive (Fig. 2h–k). The effect of 5′-UTR mirtrons on downstream gene expression was determined by fluorescence spectroscopy using lysates derived from transfected HEK293 cells. A single mirtron within the 5′-UTR had no effect on transgene expression whilst a modest reduction in fluorescence was observed when two mirtrons were included (Supplementary Fig. 2).

**Assessment of codon-modified human rhodopsin.** For an effective knockdown/replacement vector, the RHO within the AAV must be resistant to co-expressed mirtrons. To achieve this, codons constituting the target sites for the most effective mirtrons
(M3 and M5) were exchanged, where possible, for alternative sequences encoding the same amino acids (synonymous codons). Human and mouse codon frequencies were considered, and rare codons avoided\(^4\),\(^3\). The 21 bp M3 target site of human RHO was thus modified from CTTCCTCCAATCACTTCTCAC to ATTTTCCAATTAATTTCCTGAG, whilst the human/mouse M5 target site was modified from AACGAGTCTTTTGTCATCTAC to AATGAATCCTTCGTGAA at the time of injection resulting in a shallow retinal detachment, whilst in another significant intraoperative subretinal haemorrhage was noted. All animals showing high ERG signal after treatment had documented uncomplicated good quality injections. In two of the treated eyes with no documented surgical complications, a low ERG signal was recorded. We attribute this to possible trans-scleral reflux of the vector observed at the time of injection resulting in a shallow retinal detachment, whilst in another significant intraoperative subretinal haemorrhage was noted. All animals showing high ERG signal after treatment had documented uncomplicated good quality injections. In two of the treated eyes with no documented intraoperative complications, a low ERG signal was recorded. We attribute this to possible trans-scleral reflux of the vector after completion of the injection. Immunohistochemistry (IHC) revealed that treated retinas had OS that were absent in Nrl.GFP/+ , Rho\(^{−/−}\) mice, a rescue of the rod-derived electroretinogram (ERG) was achieved confirming functionality of the codon-modified transgenic protein (Fig. 3d). The ERG response of treated eyes was variable. Of the four treated eyes which gave the lowest signal, two had documented surgical complications: one had substantial transscleral reflux of the vector observed at the time of injection resulting in a shallow retinal detachment, whilst in another significant intraoperative subretinal haemorrhage was noted. All animals showing high ERG signal after treatment had documented uncomplicated good quality injections. In two of the treated eyes with no documented intraoperative complications, a low ERG signal was recorded. We attribute this to possible trans-scleral reflux of the vector after completion of the injection. Immunohistochemistry (IHC) revealed that treated retinas had OS that were absent in...
uninjected fellow eyes. These were packed with rhodopsin (Fig. 3). No ectopic rhodopsin expression (i.e. outside of the rod OS) was identified (Fig. 3f). Thus, human rhodopsin protein translated under the control of a rod cell-specific promoter from an mRNA transcript resistant to both mirtrons 3 and 5 trafficked to the OS of rods, and is capable of driving the dark-adapted light response.

Splicing efficiency of artificial mirtrons in vivo. To confirm that mirtrons are liberated from transgenic mRNA in vivo, Nrl.GFP/+; RhoP23H/+ mice were injected subretinally with an AAV vector (pseudotype AAV2/8 with Y733F capsid mutation) combining M3 and M5 in tandem within the 5′-UTR of RHOM3/5R (AAV-M3.M5H.RHOM3/5R; Fig. 4a). The Nrl.GFP/+; RhoP23H/+ knock-in mouse carries the dominant P23H rhodopsin mutation along with a rod-specific eGFP reporter which permits en face imaging of the surviving rod cell population in vivo. Right eyes were injected with vector at either low (2 × 10^9 gc) or high dose (2 × 10^10 gc), whilst left eyes received subretinal sham injections of phosphate-buffered saline (PBS). Four weeks later, retinas were harvested and cDNA derived. Subsequent PCR analysis using mirtron-spanning primers revealed predominant bands corresponding in size to those expected from transcripts in which both mirtrons had been individually spliced (Fig. 4b, c). Correct splicing in vivo was confirmed by Sanger sequencing of M3 (Fig. 4d).

Mirtron-derived miRNA expression and rhodopsin RNA replacement in vivo. Small RNA expression analysis was performed using whole retinal samples 4 weeks after unilateral subretinal delivery of AAV-M3.M5H.RHOM3/5R in Nrl.GFP/+; RhoP23H/+ mice (n = 5 for each low dose and high dose). Retinas from sham (PBS)-injected fellow eyes were processed in a similar fashion as internal controls. Sequence reads of 15–31 nucleotides were searched against micro RNAs in the microRNA database (miRbase 22), and all unannotated sequences representing potentially novel miRNAs were quantified and analysed. The 21
Fig. 4 Artificial mirtrons delivered by a recombinant AAV vector are efficiently spliced from transgenic pre-mRNA in vivo. a Genome map of AAV-M3. M5H.RHOM3/5R. Size in bp is indicated above each element and locations of relevant restriction sites marked. Size of the entire genome is shown to the right. ITR: inverted terminal repeat, RHOp: human rhodopsin promoter, Ex/Int: Exon/intron/exon splice site from the CAG promoter, RHOM3/5R: codon-modified RHO coding sequence, WPRE: woodchuck hepatitis virus post-transcriptional regulatory element, pA: bovine polyadenosine signal. b Artificial mirtrons delivered by a recombinant AAV vector are efficiently spliced from transgenic mRNA in vivo. DNA gel electrophoresis of ampiclons generated using mirtron-spanning primers with template cDNA derived from AAV-M3.M5H.RHOM3/5R-injected samples but not in sham-injected fellow eyes (Fig. 5a). Sequence analysis confirmed accurate production of the 21 bp mature miRNA species from guide strands of both M3 (Fig. 5b) and M5H (Fig. 5c). In both cases, the 5′ end was more precisely generated (through splicing) than the 3′ end (generated by Dicer25). Short RNA corresponding to the passenger strand of M3 was detected in very low quantities by comparison (Fig. 5b), whilst none was detected for M5H (Fig. 5c). Levels of endogenous Rho knockdown and transgene-derived RHO replacement were determined by RT-qPCR using the same samples. Whole retinal gene expression studies revealed mean ± SEM knockdown of endogenous rhodopsin in eyes injected with 2 × 10^9 gc AAV-M3.M5H.RHOM3/5R of 34.1 ± 5.0% compared with fellow sham-injected contralateral eyes (Fig. 5d; p = 0.0024). No rhodopsin knockdown was detected when an equivalent mirtronless vector (AAV-RHO; referred to as AAV-Ex/Int in Orlans et al. 202023) was injected using the same experimental protocol (Fig. 5e). AAV-M3.M5H.RHOM3/5R was capable of driving expression levels of human rhodopsin comparable to those of native mouse rhopsin in sham-injected fellow eyes (Fig. 5f). For eyes injected with the AAV-M3.M5H.RHOM3/5R, but not for the mirtronless equivalent, a strong negative correlation existed between expression levels of mouse and human rhodopsin (Fig. 5g, h). Further, M3-derived miRNA expression strongly correlated with the observed degree of mouse rhodopsin suppression (Fig. 5i). AAV-M3.M5H.RHOM3/5R thus functions as a rhodopsin mRNA replacement vector with a clear dose–response relationship. This represents the first demonstration to date of gene suppression by an artificial mirtron in vivo.

Effect of mirtron-mediated RNA replacement therapy in vivo. AAV-M3.M5H.RHOM3/5R was injected at one of two doses, 2 × 10^9 gc (low dose, n = 17) or 2 × 10^9 gc (high dose, n = 17), into the right eyes of Nrl.GFP/+, Rho^P23H/+ mice, whilst left eyes remained un.injected, acting as internal controls. The effect on retinal structure and function was determined longitudinally in vivo by spectral domain optical coherence tomography (SD-OCT)/confocal scanning laser ophthalmoscopy (cSLO) and ERG respectively. The effect of sham injection had been determined using an identical protocol in a previous study in which a slight reduction in SD-OCT photoreceptor layer (PRL) thickness (defined as the vertical distance between the outer plexiform layer and RPE bands37) and ERG signal was observed in sham-injected relative to fellow uninjected eyes attributable to the surgical procedure25. Treatment here with low dose AAV-M3.M5H.RHOM3/5R by contrast resulted in a significant slowing of retinal degeneration in the Nrl.GFP/+, Rho^P23H/+ mouse as recorded by SD-OCT (Fig. 6a, b), cSLO fluorescence imaging (Fig. 6c) and ERG (Fig. 6d, e), an effect which was not observed when the equivalent but mirtronless AAV-RHO vector was injected at the same dose (Fig. 6f). The effect of treatment on PRL thickness as a function of retinal location is shown in Supplementary Fig. 3 whilst detailed ERG data are shown in Supplementary Figs. 4 and 5. At high dose, an effect size between that observed for low dose and sham-injected cohorts was evident (Supplementary Figs. 3–5) which may be attributable to a degree of rhodopsin overexpression (Fig. 5b).

Discussion
In this study we have developed a mutation-independent approach to the treatment of rhodopsin-related ADRP using artificial mirtrons. We have shown that the resulting vector can achieve RNA replacement and a modest slowing of retinal degeneration in a rapidly-
Fig. 5 Micro RNA expression and gene expression analysis of knockdown and replacement arms of AAV-M3.M5\(^{H}\).RHO\(^{M3/5R}\) gene therapy 4 weeks after subretinal injection in the Nrl.GFP/\(^{+}\), RhoP23H/\(^{+}\) mouse. Gene expression levels refer to the ratio Rhodopsin: eGFP (note eGFP expression is rod-specific in this model\(^{36}\). a Small RNA expression analysis detected mirtron-derived 21 bp mature miRNAs corresponding to Mirtron 3 (M3) and Mirtron 5\(^{H}\) (M5\(^{H}\)) guide sequences in AAV-injected but not in sham-injected eyes. b Short RNA sequencing (15-31 nt) from high-dose AAV-M3.M5\(^{H}\).RHO\(^{M3/5R}\)-treated retinas aligned to the Mirtron 3 sequence. c Short RNA sequencing (15-31 nt) from high-dose AAV-M3.M5\(^{H}\).RHO\(^{M3/5R}\)-treated retinas aligned to the Mirtron 5\(^{H}\) sequence. d Suppression of endogenous mouse rhodopsin gene expression by AAV-M3.M5\(^{H}\).RHO\(^{M3/5R}\). Paired right (AAV-injected) and left (sham PBS-injected) eyes are connected by joining lines. **\(p = 0.0024\), two-way ANOVA, Šidák’s multiple comparisons test. e No suppression of endogenous mouse rhodopsin was detected at either dose in eyes injected with the mirtronless AAV-RHO vector. Paired right (AAV-injected) and left (sham PBS-injected) eyes are connected by joining lines. Two-way ANOVA, Šidák’s multiple comparisons test. f Human transgenic rhodopsin supplementation levels in AAV-M3.M5\(^{H}\).RHO\(^{M3/5R}\)-injected retinas expressed as fold change relative to endogenous mouse rhodopsin in fellow eyes. **\(p = 0.0011\), two-sided Šidák’s multiple comparisons test. g Scatter plot of human RHO versus mouse Rho gene expression relative to eGFP housekeeper following subretinal injection of AAV-M3.M5\(^{H}\).RHO\(^{M3/5R}\) as determined by qPCR (\(r^2 = 0.731\), \(p = 0.0016\)). Trend lines represent linear regression ± 95% confidence interval (dotted lines). h Scatter plot of human RHO versus mouse Rho gene expression relative to eGFP housekeeper following subretinal injection of AAV-RHO (mirtronless human rhodopsin vector) as determined by qPCR (\(r^2 = 0.005923\), \(p = 0.844\)). i Scatter plot of mouse Rho gene expression as a function of Mirtron-3-derived miRNA expression in eyes receiving subretinal injection of AAV-M3.M5\(^{H}\).RHO\(^{M3/5R}\) at low \(2 \times 10^8\)gc and high \(2 \times 10^9\)gc dose (\(r^2 = 0.670\), \(p = 0.004\)).
degenerating clinically relevant knock-in mouse model. The observed efficacy here may be directly attributable to the inclusion of rhodopsin-targeting mirtrons as an equivalent but mirtronless vector failed to impart any measurable benefit in a parallel study using the same experimental protocol. Knockdown/replacement gene therapy has been demonstrated in transgenic models of ADRP using rhodopsin-targeting shRNAs under the control of Pol-III promoters together with codon-modified rhodopsin supplementation under rod-specific Pol-II promoter control. These studies have either employed separate suppression and supplementation vectors, or have combined the two therapeutic arms driven by separate promoters within a single AAV. Since various alternative mouse models of ADRP were used by these researchers, the magnitude of reported treatment effects cannot be compared directly with that reported here. In a recent study, Tsai et al. developed a novel dual vector CRISPR-Cas9-based knockdown/replace-ment treatment strategy, which they validated in the P23H and D190N knock-in mouse models of ADRP. In spite of differences in the timing of treatment (these authors injected mice at post-natal day 1–3), the magnitude of functional rescue they observed in the RhoP23H/+ model, as measured by ERG, is broadly comparable to that achieved with our mirtron-based vector.
Although introducing additional target sequence constraints, the application of artificial mirtrons for knockdown/replacement gene therapy confers several potential advantages over other RNAi-based approaches, namely the by-passing of a potential molecular bottleneck (Drosophila/DGC8R)\textsuperscript{35}, more accurate generation of the critical 5’ seed region of the guide strand (Fig. 5b, c)\textsuperscript{33,34,40}, and cell-specific RNAi expression\textsuperscript{29,31}. In addition, the single-promoter construct developed here allows for consistent matching between the therapeutic arms within any given cell, which may reduce the risk of toxicity related to any imbalance between rhodopsin suppression and supplementation\textsuperscript{11,32,41-43}. Direct comparison studies using equivalent vectors would be required to determine whether these theoretical advantages of mirtron-based knockdown/replacement gene therapy are borne out in practice.

Splicing efficiency for mirtrons M1–7 varied dramatically, from <1% (M1) to near 100% (M5). These designs, with the exception of M4, fulfilled the criterion of Seow et al. for design of artificial mirtrons that sequences commence with a GURRR motif\textsuperscript{29}. M4 had a C at position +5 but was nevertheless spliced efficiently from its parent transcript. Conversely, M1 met this criterion but very little splicing was detected from the intended 5’ donor site. The presence of three purines at positions +3 to +5 did not therefore predict robust splicing of mirtrons in this study. Further, the 5’ donor splice sites of the efficiently spliced mirtrons M5 and M7 differed between positions +4 and +6 from those that define the canonical splice consensus of GURAGU\textsuperscript{43} by 2 and 1 nucleotides respectively. This region of the intron is critical for donor splice site recognition by small nuclear RNA components of the spliceosome\textsuperscript{44,45}. Taken together, these data would suggest that a variety of splice donor sites can result in effective liberation of mirtrons from transcripts, and that splicing efficiency of artificial mirtrons must be determined empirically.

A proportion of transcripts for all seven mirtron designs spliced incorrectly as a result of cryptic splice donor/acceptor sites. The presence of alternative splice products provides a compelling argument for locating mirtrons within the 5’-UTR rather than the CDS of a transgene. In the latter case, mis-splicing could result in production of mutant protein or NMD for frame shifts. Mis-splicing of mirtrons within the 5’-UTR would however have minimal impact on downstream gene expression, and importantly would not affect transgenic protein structure.

In their in vitro study, Curtis et al. combined artificial mirtrons with a replacement transgene under the control of a single Pol-II promoter as part of a knockdown/replacement gene therapy construct for spinocerebellar ataxia\textsuperscript{7,31}. The authors found that mirtrons that spliced efficiently from within the CDS of GFP failed to do so in other contexts, stipulating that the mirtron’s hairpin secondary structure may have restricted spliceosome access. They further postulated that a lack of exonic splice enhancers (ESEs: hexameric motifs within exons that support accurate and efficient splicing of nearby introns) at alternative locations may have contributed to this effect. Here, 5’ and 3’ flanking regions of the eGFP reporter in which splicing and potency of mirtrons had initially been validated were included alongside the mirtron when cloned into the 5’-UTR. This ensured that the ESE-rich context from which mirtrons were so effectively spliced was preserved. This strategy is only possible for mirtron placement in the UTR region of a transcript as additional nucleotides flanking a mirtron located within the CDS would disrupt translation post-splicing. Placement within the 5’-UTR also allowed multiple mirtrons to be co-expressed alongside the replacement gene. Curtis et al. found that delivery of multiple mirtrons as separate introns within the CDS of a transgene adversely affected splicing efficiency\textsuperscript{31}. This may have explained why they observed no significant increase in overall potency for double- versus single-mirtron constructs. In this study, 5’-UTR mirtrons were individually and accurately spliced and had additive suppressive effects against rhodopsin targets. Inclusion of two or more independently functioning mirtrons in tandem within the 5’-UTR may be a useful general strategy for knockdown/replacement gene therapy application, as it potentially allows a construct to retain efficacy even when the point mutation carried by an individual falls within the one of the target regions. Tandem mirtrons could also be applied for the treatment of complex non-Mendelian disease, where they might be used to suppress the expression of multiple genes within a molecular pathway\textsuperscript{45}.

In this study a modest rescue effect was observed following treatment of rapidly-degenerating adult mice with established disease. This contrasts with earlier studies in which younger mice with a slower degenerating phenotype were treated during the period of retinal development\textsuperscript{44,45}. Treatment with 2 × 10\textsuperscript{9} gc was found to be more effective than treatment with 2 × 10\textsuperscript{8} gc of AAV-M3.M5H\textsuperscript{44}, RHO\textsuperscript{34,35} which may be due to a degree of retinal toxicity as a result of over-replacement of rhodopsin\textsuperscript{45}. Optimisation of the AAV construct, for example through inclusion of additional rhosopsin-targeting mirtrons and/or weakening of the expression cassette to reduce human rhodopsin expression, may further improve efficacy of future iterations of the knockdown/replacement vector developed here. The human RHO-targeting version of M5 (M5\textsuperscript{31}) was chosen for use in the in vivo part of this study in anticipation of future human translation. This mirtron would not be expected to be active in mice (see Fig. 1f). The rhodopsin-suppressing effect of the vector described might therefore be expected to be greater when applied to human subjects. Further, since only rhodopsin target sites within areas of homology between human and mouse transcripts were considered in this study, it is possible that more effective species-specific mirtrons may be identified whose target sites fall outside of these regions.

In summary, this study represents the first in vivo demonstration of RNA replacement gene therapy using artificial mirtrons. This strategy has several advantages over existing techniques and may be broadly applied for the treatment of any dominantly-inherited disease.

Methods

Design of candidate mirtrons. The core structure of mirtrons used in this study is born out of the 3’-tailed design described and validated by Kock et al.\textsuperscript{15,16}. The advantage of artificial 3’-tailed over canonical mirtrons is that they have fewer sequence constraints by virtue of the intronic branch point and polypyrimidine tract being located outside of the stem-loop structure which contains the guide strand (Supplementary Fig. 6). For all artificial mirtrons used in this study, the guide strand was located in the 5’ arm of the hairpin stem, rather than the 3’ arm where cellular processing may be less accurate\textsuperscript{44}. The guide strand was connected to a complementary 3’ passenger arm by a TTAACAGAG loop motif. Mismatches between guide and passenger strands of the stem were purposefully introduced at the 5’ end to reduce local internal stability and facilitate correct selection of the guide strand (as opposed to the passenger strand) by the RNAi-induced silencing complex (Supplementary Fig. 7a-h)\textsuperscript{46,47}.

Potential targets for artificial mirtrons within the rhodopsin cDNA sequence were identified according to several criteria. Firstly, only areas of at least 21 bp in length with perfect or near-perfect homology between the mouse and human rhodopsin mRNA transcript were considered. This was required for incorporation into a treatment for ADRP in man could first be validated in a relevant mouse model. Secondly, since a 21 bp guide sequence located within the 5’ arm of a mirtron must commence with a splice donor motif, only potential target sequences that featured the reverse complement of such a motif at their 3’ end were considered. Thirdly, mirtron candidates that contained an additional strong splice donor motif elsewhere within the 21 bp guide sequence were not considered as such mirtrons would likely be preferentially spliced incorrectly.

Candidate mirtron sequences nested within the eGFP CDS were input into online splice prediction software (SplicePort: http://spliceport.cbcb.umd.edu and HumSpliceFinder: http://www.umd.be/HSF/HSF.shtml) to identify those that included strong donor motifs. Scores for the mirtrons that were subsequently manufactured and tested in vitro are shown in Supplementary Table 1. The siRNA at Whitehead online RNAi prediction tool (http://siRNA.wi.mit.edu) was also used to identify which candidate sequences were likely to make effective RNAi targets. With the above in mind, seven 3’-tailed mirtrons (designated M1–M7) were designed targeting different parts of the rhodopsin CDS (Supplementary Fig. 7). The 21 bp guide sequences of M1–4 and M6 were perfect antisense matches to both
the human and mouse transcripts. That of M7 was a complete antisense match for the human CDS, but contained a single mismatch with the mouse sequence. This mismatch would never be predicted to form a non-wobble base pair at the RNA level, and so may nonetheless allow effective targeting by this mirtron. The sequence targeted by M5 was identified by the siRNA at Whitehead online tool as a strong candidate for effective RNAi-induced cleavage. The mouse and human M5 targets however differed by two base pairs. Two versions of M5 were therefore created: M5G matching the reverse complement of the human CDS, and M5M matching that of the mouse sequence.

The guide strand and target sequences together with their respective target positions within the rhodopsin CDS are shown in Supplementary Table 2.

Cloning. Double stranded mirtron inserts with 5′ and 3′ overhangs complementary to those of the BstB1 restriction site were engineered by annealing complementary oligonucleotides. Forward oligonucleotides comprised the desired 76 bp mirtron sequence (which by design already had BstBI adhesive ends) and reverse oligonucleotides comprised the reverse complement of the desired mirtron sequence with omission of the 5′-CTT motif, a 5′ phosphate and inclusion of CTT at the 3′ end. Oligonucleotides were manufactured by Sigma-Aldrich, UK, and reconstituted to a concentration of 10 μM upon receipt. 5′ forward and 3′ reverse solution were thoroughly mixed and heated to a temperature of 95 °C for 5 min using a PCR thermocycler (Multigene, Labnet International Inc.). Samples were then slowly cooled in a stepwise manner to room temperature over a period of 6 min to facilitate efficient annealing. The resulting double stranded mirtron sequence (which by design already had BstBI adhesive ends) was ligated directly into the BstB1/shrimp alkaline phosphatase (both New England Biolabs, UK) treated CAG.GFP.WPRE plasmid backbone. The eGFP CDS is shown below. The BstB1 restriction site is underlined, with the cut point marked by a vertical line:

```
ATGACGGGAGGCGAAGAACCTGATCTGAGTCTTCCATATTCTCGTGGACCTGGATGACACAGGAA
CGGAGGGGCTGGTGAAGGTGTTGACTCAGTACATGAGACGTTTCTAC
```

Correct orientation of the mirtron within the construct was confirmed by commercial Sanger sequencing with primer sequence 5′-CCACAATTCTGTCGACG (Source Biosciences, UK). To evaluate the efficacy of mirtrons, human and mouse rhodopsin target sequences were subcloned from plasmid DNA and murine retinal cDNA respectively into the multiple cloning site (MCS) and BstB1 adhesive ends was ligated directly into the BstB1/shrimp alkaline phosphatase (both New England Biolabs, UK) treated CAG.GFP.WPRE plasmid backbone. The eGFP CDS is shown below. The BstB1 restriction site is underlined, with the cut point marked by a vertical line:

```
ATGACGGGAGGCGAAGAACCTGATCTGAGTCTTCCATATTCTCGTGGACCTGGATGACACAGGAA
CGGAGGGGCTGGTGAAGGTGTTGACTCAGTACATGAGACGTTTCTAC
```

Optimisation of 5′-UTR mirtron flanks. Splicing of mirtrons is context dependent and reliant of the presence of nearby exonic splice enhancer sequences (ESEs). To evaluate the effect of mirtron splicing within the 5′-UTR on downstream translational readthrough. The original mirtron insertion site within eGFP were also included (i.e. around the BstB1 restriction site where efficient splicing had already been confirmed), as these were found to contain numerous ESses (as identified using the online RESCUE-ESE tool48, http://genos.miit.edu/burgelab/rescue-ese). An in silico splice analysis was performed using various splicing prediction software such as MirtronPredict, which was then normalised to that recorded from cell samples transfected with the mirtronless CAG.GFP.WPRE plasmid.

Fluorescent spectroscopy. Fluorescent spectroscopy assays were performed for quantification of splicing for mirtron constructs nested within the eGFP CDS, and for assessment of the effect of 5′-UTR mirtrons on downstream transgene expression. For the splicing assay, HEK293 cells were seeded into 12 well plates and transfected with 1 μg pCAG.eGFP.WPRE or pCAG.eGFP-M1-7.WPRE. For gene expression assays, cells were transfected with 2 μg pCAG.eGFP-WPRE or Mirtron-UTR plasmid. In either case, wells were photographed 48 h later using a fluorescence reader (Bio-Rad, UK). For each sample, 10 μl of protein lysate was loaded into wells of a black microtiter plate and luminescence signal was then recorded (in arbitrary units) using the appropriate substrate for Firefly luciferase (Promega, USA) in accordance with manufacturer's instructions. This colourimetric assay quantifies protein of appropriately diluted samples against a standard curve of bovine serum albumin of known concentration. All reactions were performed in duplicate, and colourimetric absorbance readings taken at 562 nm using the iMark microplate reader (BioRad, UK). For each sample, 10 μl of protein was loaded into a black plastic 96 well plate (Greiner Bio-One, UK) and the volume made up to 300 μl with FIPA buffer (Promega, USA). Fluorescence (in arbitrary units) was measured using the Viktor® 1420 Multilabel plate reader (Perkin Elmer, UK), with excitation at 485 nm, and detection at 535 nm and an exposure time of 1 s per well. To account for background fluorescence, the mean reading taken from protein lysates derived from untransduced cells was subtracted from all transduced cell fluorescence readings. Signals obtained from protein lysates extracted from pCAG.eGFP-WPRE or Mirtron-UTR transfected cells were then normalised to that recorded from pCAG.eGFP.WPRE transfected cell lysates to obtain a measure of splicing efficiency, or normalised reporter gene expression respectively.

Luciferase assays. For the Dual Glo® assay, HEK293 cells were seeded into 96 well culture plates. After 24 h, cells were co-transfected with 65 ng mirtron plasmid and 32.5 ng pCheck2-target plasmid. Forty-eight hours later, 30 μl of media was removed from each well and the assay performed in accordance with manufacturer’s instructions. Briefly, 70 μl of Renilla luciferase substrate was added to each well and the plate left to incubate for 20 min. Renilla luciferase luminescence signal was then recorded (in arbitrary units) using the Viktor® plate reader. Seventy μl of Stop & Glo reagent (which quenches Renilla luciferase activity and includes the substrate for Firefly luciferase) was then added to each well and the plate again left to incubate at room temperature for 20 min. Firefly luminescence was then similarly read (in arbitrary units) using the Viktor® plate reader. Mirtron-mediated mRNA knockdown was estimated by calculating the relative ratio of Renilla/Firefly, which was then normalised to that recorded from cell samples transfected with the mirtronless CAG.GFP.WPRE plasmid.

Immunocytochemistry. Immunocytochemistry was performed on HEK293 cells cultured in chamber slides (Nunc Lab-Tek II chamber slide system39, Thermofisher
Scientific, UK) 48 h after transfection. Media was removed from the cell monolayer and two PBS washes were applied, each consisting of the gentle addition and removal of 120 µl of 0.1 M PBS. Cells were fixed in 120 µl 4% formaldehyde (Thermo Fisher Scientific, UK) for 15 min at room temperature followed by two further PBS washes as above. Cells were then permeabilised by incubation in 120 µl 0.2% Triton X-100 in 0.1 M PBS for 10 minutes, washed once in PBS and incubated in 120 µl 10% normal donkey serum (NDS) with 0.1% Triton X-100 in 0.1 M PBS for 30 min. After a further PBS wash, the specimens were incubated in 100 µl primary antibody: Rh–GFP–/– was a rhodopsin knockout mouse with a GFP transgene under the control of the Nrl promoter. The second, designated NrlGFP/+; Rh–, was a knock-in mouse carrying a heterozygous P23H mutation at the rhodopsin locus, also with an a GFP transgene under the control of the Nrl promoter. Inclusion of the NrlGFP transgene in these models allowed dynamic en face imaging of the surviving population of rods using blue auto fluorescence imaging cSLO. Detailed descriptions of these models and techniques may be found elsewhere.

In vivo procedures. For all in vivo procedures, mice were anaesthetised with a combination of ketamine (Vetalar, Boehringer Ingelhelm, Bracknell, UK; 80 µg/g body weight) and xylazine (Rompun; Bayer, Reading, UK; 10 µg/g body weight) diluted in sterile 0.9% saline, delivered by intraperitoneal injection. Pupils were then dilated with tropicamide 1% and phenylephrine 2.5% eye drops (both Bausch & Lomb, Kingston upon Thames, UK). Where appropriate anaesthesia was reversed at the end of procedures by intraperitoneal injection of atipamezole (Antisedan, Zoetis, Leatherhead, UK; 2 mg/kg body weight) diluted in sterile 0.9% saline.

Subretinal injections. Animals in this study received single unilateral subretinal injections of PBS (‘Sham’) or AAV at a dose of either 1 × 10^5 gc/ml (‘Low dose’) or 2 × 10^5 gc/ml (‘High dose’), with total volume of 1.5 µl in all cases. All injections were performed by a single operator in a trac-tor seat approach in mice at postnatal week 3. Prior to injection, animals were anaesthetised and pupils diluted as described above. A drop of proparacaine (Minims, Bausch & Lomb, Kingston upon Thames, UK) was applied and a corneal paracentesis was performed by brief puncture using a 33G needle to allow efflux of a small bleb of aqueous. Carborner gel (ViscoTears Liquid Gel, Alcon, Camberley, UK) was placed on the corneal surface followed by a 5 mm glass coverslip which allowed direct visualisation of the posterior pole through the operating microscope. The transcleral subretinal injection was then performed by passing a 35G bevelled Nanofil needle mounted on a Nanofil 10 µl syringe (both World Precision Instruments, Hitchin, UK) into the subretinal space under direct visualisation. Following the procedure, the glass coverslip was removed and a drop of chloramphenicol 0.5% (Bausch & Lomb, the United Kingdom) drops were applied and polymethyl methacrylate contact lenses (Hemell Hempstead, UK). Details of antibodies used are outlined in Supplementary Table 5.

Animal models. Mice were housed in a dedicated facility at 20–24 °C and 45–65% humidity with a 12 h light/dark cycle and food and water available ad libitum. All animal procedures were conducted in accordance with the Animals (Scientific Procedures) Act 1986, UK and with the Association for Research in Vision & Ophthalmology (ARVO) statements on the care and use of animals in ophthalmic research under a UK Home Office Personal and Project License. All such experiments were approved by the University of Oxford Animal Ethics Committee. Two transgenic lines were used in this study. The first, designated NrlGFP–/–; Rh–, was a rhodopsin knockout mouse with a GFP transgene under the control of the Nrl promoter. The second, designated NrlGFP+/–; Rh–GFP–, was a knock-in mouse carrying a heterozygous P23H mutation at the rhodopsin locus, also with a GFP transgene under the control of the Nrl promoter. Inclusion of the NrlGFP transgene in these models allowed dynamic en face imaging of the surviving population of rods using blue auto fluorescence imaging cSLO. Detailed descriptions of these models and techniques may be found elsewhere.

Immunohistochemistry. Follow euthanasia, eyes for IHC were extracted and the anterior segments (cornea, iris, and lens) were removed. Eye cups were fixed in 4% formaldehyde for 30 min and then moved sequentially into 10%, 20%, and 30% sucrose solutions, for at least 20 min each. The eye cups remained in 30% sucrose solution overnight at 4 °C, were washed in PBS, dried, and then submerged in optimal cutting temperature compound (VWR International, Lutterworth, United Kingdom) within a mold. The molds were transferred to dry ice to induce freezing and the specimens cut to a thickness of 18 microns using a cryostat. Sections were placed on polylysine-coated glass slides and left to dry at room temperature overnight. The slides were subsequently incubated in 0.2% Triton X-100 in PBS for 20 min and then blocked in 10% NDS-PBS for a period of 1 h. Primary rabbit anti-rat anti-rabbit IgG (65–86 antibody (Alexa Fluor ab175470; Abbam, Cambridge, United Kingdom) diluted 1:1000 in PBS with 1% NDS was placed onto the sections, and slides were left to incubate overnight at 4 °C. Slides were then incubated with secondary fluorescent-tagged donkey anti-rabbit IgG–568 antibody (Cayman; abcam, Cambridge, United Kingdom) diluted 1:500 in PBS containing 1% NDS for 2 h at room temperature. The sections were counterstained with Hoechst 33342 (Thermo Fisher Scientific, Hemel Hempstead, United Kingdom) and mounted with Prolong Diamond Antifade Mounting Medium (Thermo Fisher Scientific). Confocal imaging was performed using an LSM-710 inverted confocal microscope (Carl Zeiss, Cambridge, United Kingdom).

Gene expression analysis. RNA was extracted from neural retina using the mirNeasy Mini kit (Qiagen, Manchester, UK) in accordance with manufacturer's instructions. Genomic DNA contaminants were removed as part of this process using an RNase-free DNase set (Qiagen, Manchester, UK). RNA was reverse transcribed using the Invitrogen SuperScript III kit (Thermo Fisher Scientific, Hemel Hempstead, UK) and a starting quantity of 1 µg nucleic acid. TaqMan assays for human rhodopsin, mouse rhodopsin and EGFP (Thermo Fisher Scientific, Hemel Hempstead, UK) were applied using the resulting cDNA for evaluation of gene expression. The CFX Connect™ real-time PCR detection system (Bio-Rad, Watford, UK) was used for real-time quantitative PCR (RT-qPCR) with the fol-owing thermal cycling conditions: polymerase activation period at 95 °C for 10 min, followed by 40× PCR cycles of denaturation at 95 °C for 10 s and annealing/ extension at 60 °C for 1 min.

Small RNA expression analysis. Small RNA expression analysis was performed on RNA samples used for gene expression analysis by Genewiz Inc., South Plainfield, NJ, USA.

Statistical analysis. All grouping and statistical analysis was performed using Prism software (Version 7.0a, GraphPad Inc., USA). Quantitative measures and errors are presented as mean ± standard error of the mean (SEM) unless otherwise stated. Where data sets were large enough, the Shapiro–Wilk test for normality was performed and, if established, parametric tests applied. When two matched or unmatched groups were to be compared, paired or unpaired two-tailed t-tests were performed using the Invitroscript III kit (Thermo Fisher Scientific, Hemel Hempstead, UK) and a starting quantity of 1 µg nucleic acid. TaqMan assays for human rhodopsin, mouse rhodopsin and EGFP (Thermo Fisher Scientific, Hemel Hempstead, UK) were applied using the resulting cDNA for evaluation of gene expression. The CFX Connect™ real-time PCR detection system (Bio-Rad, Watford, UK) was used for real-time quantitative PCR (RT-qPCR) with the fol-owing thermal cycling conditions: polymerase activation period at 95 °C for 10 min, followed by 40× PCR cycles of denaturation at 95 °C for 10 s and annealing/ extension at 60 °C for 1 min.

Small RNA expression analysis. Small RNA expression analysis was performed on RNA samples used for gene expression analysis by Genewiz Inc., South Plainfield, NJ, USA.

Statistical analysis. All grouping and statistical analysis was performed using Prism software (Version 7.0a, GraphPad Inc., USA). Quantitative measures and errors are presented as mean ± standard error of the mean (SEM) unless otherwise stated. Where data sets were large enough, the Shapiro–Wilk test for normality was performed and, if established, parametric tests applied. When two matched or unmatched groups were to be compared, paired or unpaired two-tailed t-tests were performed using the Invitroscript III kit (Thermo Fisher Scientific, Hemel Hempstead, UK) and a starting quantity of 1 µg nucleic acid. TaqMan assays for human rhodopsin, mouse rhodopsin and EGFP (Thermo Fisher Scientific, Hemel Hempstead, UK) were applied using the resulting cDNA for evaluation of gene expression. The CFX Connect™ real-time PCR detection system (Bio-Rad, Watford, UK) was used for real-time quantitative PCR (RT-qPCR) with the following thermal cycling conditions: polymerase activation period at 95 °C for 10 min, followed by 40× PCR cycles of denaturation at 95 °C for 10 s and annealing/extension at 60 °C for 1 min.
1. Verbakel, S. K. et al. Non-syndromic retinitis pigmentosa. *Prog. Retin. Eye Res.* 0–1 (2018). https://doi.org/10.1016/j.preteyeres.2018.03.005.

2. Russell, S. et al. Efficacy and safety of vetricogene necarvovec (AAV2-hRPE65v2) in patients with RP65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet* 390, 849–860 (2017).

3. Xue, K. et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. *Nat. Med.* 24, 1507–1512 (2018).

4. Cehajic-Kapetanovic, J. et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. *Nat. Med.* 26, 354–359 (2020).

5. Miller, J. W. & Vandenbergh, L. H. Breaking and Sealing Barriers in Retinal Gene Therapy. *Mol. Ther.* 26, 2081–2082 (2018).

6. Daiger, S. P., Sullivan, L. S. & Bowie, S. J. RetNet Retinal Information Network. https://sph.uth.edu/retnet/disease.htm#03.202d (2018).

7. Mendes, H. F., van der Spuy, J., Chapple, J. P. & Cheetham, E. M. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. *Trends Mol. Med.* 11, 177–185 (2005).

8. Nickell, S., Park, P. S.-H., Baumeister, W. & Palczewski, K. Three-dimensional architecture of murine rod outer segments determined by cryoelectron tomography. *J. Cell Biol.* 177, 917–925 (2007).

9. Ahasanzio, D. et al. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. *Prog. Retin. Eye Res.* 62, 1–23 (2017).

10. Lewin, A. S., Rossmiller, B. & Mao, H. Gene Augmentation for adRP gene therapy in a mouse model of autosomal dominant retinitis pigmentosa. *Hum. Gene Ther.* 22, 1054–1064 (2013).

11. Curtis, H. J., Seow, Y., Wood, M. J. & Varela, M. A. Knockdown and replacement with a single AAV vector. *Nat. Genet.* 45, 913–917 (2013).

12. Curtis, H. J., Sibley, C. R. & Wood, M. J. A. Artificial mRNA-mediated gene knockdown: functional DMPK silencing in mammalian cells. *RNA* 13, 1328–1337 (2007).

13. Kock, K. H., Kong, K. W., Jang, H. C. & Seow, Y. Functional in vitro RPEA knockdown with artificial 3-tailed mirtrons defined by 5 splice site and branch point. *Nucleic Acids Res.* 43, 6568–6578 (2015).

14. Curtis, H. J., Seow, Y., Wood, M. J. A. & Varela, M. A. Knockdown and replacement therapy mediated by artificial mRNAs in spinocerebellar ataxia 7. *Nucleic Acids Res.* 1–16 (2017). https://doi.org/10.1093/nar/gkx483.

15. Maquat, L. E. Nonsense-mediated mRNA decay: splicing, translation and mRNPs dynamics. *Nat. Rev. Mol. Cell Biol.* 5, 89–99 (2004).

16. Baker, K. E. & Parker, R. Nonsense-mediated mRNA decay: terminating erroneous gene expression. *Curr. Opin. Cell Biol.* 16, 293–299 (2004).

17. Paterson, A. M. & Moazed, D. Codon usage tables and databases. *Nat. Rev. Genet.* 16(5), 233–245 (2015).

18. Orlans, H. O. et al. Filtration of Short-Wavelength Light Provides Therapeutic Benefit in Retinitis Pigmentosa Caused by a Common Rhodopsin Mutation. *Investig. Ophthalmol. Vis. Sci.* 52, 2733–2742 (2011).

19. O’Reilly, M. et al. mRNA interference-mediated suppression and replacement of rhodopsin in vivo. *Am. J. Hum. Genet.* 81, 127–135 (2007).

20. Tsai, Y. et al. Clustered Regularly Interspaced Short Palindromic Repeats-Based Genome Surgery for the Treatment of Autosomal Dominant Retinitis Pigmentosa. *Ophthalmozology* 1–10 (2018). https://doi.org/10.1016/j.opthe.2018.04.001.

21. Ma, H. et al. Pol III Promoters to Express Small RNAs: Delineation of the paper. All authors contributed to data analysis and approved the final paper.

22. Grimm, D. et al. Engineering and optimization of the mir-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. *Gene Ther.* 15, 1536–1549 (2008).

23. Pihlmann, M. et al. Adeno-associated virus-delivered polycistronic microRNA-clusters for knockdown of vascular endothelial growth factor in vivo. *Gene Med.* 14, 328–338 (2012).

24. Zhao, W. et al. mRNA expression data from a comprehensive microRNA assay. *Nat. Biotechnol.* 22, 326–330 (2004).

25. Saxena, S., Jonsson, Z. O. & Dutta, A. Small RNAs with imperfect match to human disease-associated genes with artificial mRNAs are functional in mammalian cells. *Proc. Natl Acad. Sci.* 101, 10861–10866 (2004).

26. Wang, X. Q. & Rothnagel, J. A. 5′ end variation of mature small RNAs with imperfect match to human disease-associated genes with artificial mRNAs are functional in mammalian cells. *Proc. Natl Acad. Sci.* 101, 10861–10866 (2004).

27. Lesser, C. F. & Guthrie, C. Mutations in 5′ mrRNAs that alter splice site specificity: implications for the active site. *Sci.* 262, 1982–1988 (1993).

28. Schwarz, D. S., Du, T., Sharp, P. & Burge, C. Predictive identification of exonic splicing enhancers in human genes. *Sci.* 297, 1007–1014 (2002).

29. Wang, X. Q. & Rothnagel, J. A. 5′-Untranslated regions with multiple upstream AUG codons can support low-level translation via leaky scanning and reinitiation. *Nucleic Acids Res.* 32, 1382–1391 (2004).

Acknowledgements

The authors would like to acknowledge the generous support of the Medical Research Council (UK) and Fight for Sight (UK) for providing funding for this work.

Author contributions

H.O.O., M.E.M., R.A.B. and R.E.M. conceived the experiments. H.O.O., M.E.M. and C.M.F.C. carried out the experiments. H.O.O. drafted the paper. M.E.M., C.M.F.C. and R.E.M. edited the paper. All authors contributed to data analysis and approved the final paper.

Competing interests

Authors on this paper (H.O.O., R.E.M., M.A.B.) are named inventors on two patents covering key intellectual property arising from this material, namely the AAV vector design (H.O.O., R.E.M., M.A.B., A.R.B.), and generic artificial mRNA-transgene constructs (H.O.O. & R.E.M.). Please refer to the University of Oxford. Patent international application numbers: PCT/GB2019/053036 and PCT/GB2019/053037. Patent international publications: WO 2020/084318 A1 and WO 2020/084319 A1, both published 30/04/2020. C.M.F.C. declares no competing interests.
